Pfizer likely did far more than any other enterprise to support the earth normalize from the pandemic, and it reaped a economical windfall from its twin Covid-19 franchise—the best-advertising vaccine and the primary procedure, Paxlovid.
The earth, however, has stopped stressing about Covid—and Pfizer (ticker: PFE) is paying out the cost. The sales of its two Covid blockbusters could decrease more than 60% in 2023, right after creating a merged $57 billion in income during 2022. And there is appreciable uncertainty about need for the two in the coming yrs.
